Alisertib
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201931

CAS#: 1028486-01-2

Description: Alisertib, also known as MLN8237, is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.


Price and Availability

Size Price Shipping out time Quantity
25mg USD 150 Same Day
50mg USD 250 Same Day
100mg USD 450 Same Day
200mg USD 850 Same Day
500mg USD 1850 Same Day
1g USD 3250 Same Day
2g USD 4850 Same Day
5g USD 7250 2 Weeks
10g USD 12650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-05-29. Prices are subject to change without notice.

Alisertib (MLN-8237), purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 201931
Name: Alisertib
CAS#: 1028486-01-2
Chemical Formula: C27H20ClFN4O4
Exact Mass: 518.11571
Molecular Weight: 518.9
Elemental Analysis: C, 62.49; H, 3.88; Cl, 6.83; F, 3.66; N, 10.80; O, 12.33


Related CAS #: 1028486-06-7 (sodium anhydrous)   1208255-63-3 (sodium)  

Synonym: MLN8237; MLN-8237; MLN 8237; alisertib.

IUPAC/Chemical Name: 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid

InChi Key: ZLHFILGSQDJULK-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)

SMILES Code: O=C(O)C1=CC=C(NC2=NC=C3C(C4=CC=C(Cl)C=C4C(C5=C(OC)C=CC=C5F)=NC3)=N2)C=C1OC


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information

MLN-8237 is an Aurora A kinase blocker designed to disrupt the cycle of cancer cells. It is being tested in several types of cancer as monotherapy and in combination with different chemotherapy regimens. Millennium expects MLN-8237 to progress to mid-stage trials later in 2009. If MLN-8237 survives the clinical trial process, it may become the first approved therapy in the Aurora A kinase blocker class. Millennium is in a race, however, with research and development divisions at other pharmaceutical companies that are testing their own Aurora A kinase blockers. see: www.hcplive.com/media/pdf/May09_09PFN.pdf .
 
  Current developer:   Millennium Pharmaceuticals, Inc.
 
 


References

1. Preparation of [(phenylpyrimidobenzazepinyl)amino]methoxybenzoic acid derivatives for us as antitumor agents. Claiborne, Christopher F.; Sells, Todd B.; Stroud, Stephen G. (Millennium Pharmaceuticals, Inc., USA). PCT Int. Appl. (2008), 43pp. CODEN: PIXXD2 WO 2008063525 A1 20080529 . Patent written in English. Application: WO 2007-US23948 20071114. Priority: US 2006-859340 20061116.